Microarray comparative genomic hybridization (CGH) has proven to be a specific, sensitive, and rapid technique, with considerable advantages compared to other m ethods used for analysis of DNA copy num ber changes. Array CGH allows for the mapping of genomic copy number alterations at the sub-microspecific level, thereby directly linking disease phenotypes to gene dosage alterations. The whole hum an genom e can be scanned for deletions and duplications at over 30,000 loci simultaneously by array CGH (∼40 kb resolution). Array CGH can be used for analysis of DNA copy number aberrations that cause not only cancer and human genetic disease, but also normal human variation. This review gives the various array CGH platform s and their applications in cancer and hum an genetics. (J Lung Cancer 2011;10(2):77 86)
INTRODUCTION

Conventional comparative genomic hybridization (CGH) is a molecular cytogenetic technique that is designed for identifying
and mapping chromosomal segments with a copy number alteration of DNA sequences (1, 2) . Total genomic DNA is isolated from test and reference cell populations, differentially labeled, and hybridized to represent the genome that allows the binding of sequences at different genomic locations to be Array-based CGH improves the resolution of the technique by substituting the hybridization target, the metaphase chromosome spread, with genomic segments spotted in an array format. Over the past several years, array CGH has demonstrated its value for analyzing DNA copy number variations.
Detecting genetic aberrations and interpreting them within the context of broader knowledge facilitates identification of critical genes and pathways involved in biological processes and disease, and provides clinically relevant information. This article describes the various array CGH platforms and their application in identifying genetic alterations in cancer, genetic disease, and normal genomic variation.
CONVENTIONAL CGH
Conventional CGH has been used mainly for the identification of chromosomal regions that are recurrently lost or (typically, cyanine-3 and cyanine-5), combined, and co-hybridized to cloned DNA fragments, which are spotted on a glass slide. The sample and reference competitively bind to the spots and fluorescence intensity ratios resulting from hybridization of both DNAs are reflected by their relative quantities. (B) To reduce the false-positive error rate, the two profiles of a dye-swap experiment are compared. Data are normalized so that the ratio is set to some standard value, typically 1.0 on a linear scale or 0.0 on a logarithmic scale. Each dot on the graph represents a clone spotted on the array. Blue values to the left and red values to the right of the '1' line indicate a loss of a genomic region, blue values to the right and red values to the left indicate a gain or amplification, and blue and red values at '1' indicate no copy number change. A value of 0.5 as seen in this figure indicates a homozygous deletion. gained in tumors (4), as well as for the diagnosis (5) and prognosis of cancer (6) . Conventional CGH is an efficient technique in detecting numerical aberrations and can be used in the diagnosis of difficult cases. It has been reported that conventional CGH analysis demonstrates the presence of a partial duplication of a chromosomal segment (7) , and allows the elucidation of more complex chromosomal alterations.
Conventional CGH is also a reliable technique for detecting structural aberrations, and in specific cases, may be more efficient in diagnosing complex abnormalities than karyotyping (8) . However, conventional CGH is unable to detect mosaicism, balanced chromosomal translocation, inversions, and wholegenome ploidy changes (9) . The resolution of conventional CGH is also a major practical problem that limits its clinical application. Owing to the limitation of resolution of metaphase chromosomes, aberrations smaller than 5∼10 Mb cannot be detected using conventional CGH (3). For detection of such abnormalities, a high-resolution technique is required. The microarray-based CGH technique combines the resolution of fluorescence in situ hybridization with the whole-genome screening capacity of conventional CGH, and holds great potential for the analysis of DNA copy number changes in clinical genetics (10) .
MICROARRAY-BASED CGH
Low resolution, the main limitation of conventional CGH, is overcome (11) . Chromosomes have largely been replaced by DNA microarrays containing elements that are mapped directly to the genome sequence (11, 12) . In array CGH, the detection of aberrations is in more detail, and it is possible to map the changes directly onto the genomic sequence. Differentiallylabeled test and reference DNAs are hybridized to cloned fragments, which are spotted on a glass slide (Fig. 1) . The DNA copy number aberrations are subsequently measured by detecting intensity differences in the hybridization patterns of Although CGH studies using regional and chromosomal microarrays have yielded enormous information, these studies are naturally biased to specific areas of the genome and require a priori knowledge of regions of interest. Genome-wide arrays have been employed to overcome regional bias. The genomewide approach using cDNA microarrays was originally used in gene expression profiling (12) . The advantage of this technique is that high-level amplification and deletions can be directly correlated to changes in expression using the same platform (12, 18) . However, the low signal-to-noise ratio and variable signal intensities are major concerns with using cDNA clones as targets for detecting copy-number alterations (19) . These results from the smaller target size of cDNA clones compared with genomic LICs due to a lack of intronic regions and the varying length of the cDNA target. A moving-average of clone intensities must be calculated in order to detect single copy changes, thereby reducing the resolving power of the arrays.
In order to generate a strong signal, larger quantities (micrograms) of sample genomic DNA are required; thus, there is a limitation to the utility of cDNA array CGH (12) . Oligonucleotide arrays are also used in copy-number detection. These arrays contain 25-mer oligonucleotides originally designed to detect human single-nucleotide polymorphisms (SNPs; 24, 25) . In a method known as whole-genome sampling assays, linker-mediated PCR is performed on the sample DNA to enrich for small XbaI restriction fragments throughout the genome in order to reduce sample complexity prior to hybridization (26) . Although the reduced sample no longer represents the entire genome, this process decreases the probability of cross-hybridization to multiple short oligonucleotide targets on the array, effectively decreasing non-specific signals (24) .
The representative oligonucleotide microarray analysis (ROMA) method reduces the complexity of the genomic DNA sample to ∼2.5% of the genome via the BglII restriction enzyme and 
APPLICATIONS OF ARRAY
1) Array CGH applications to cancer genomes
Cancer is a disease characterized by genomic instability.
Many types of genetic instability result in production of point Array CGH provides a powerful entry point for studies involving cancer due to its ability to analyze DNA from a wide variety of specimens. High-resolution analysis of tumor genomes is needed for the discovery of genes involved in the disease. This is evident for two main reasons (19) . First, high-resolution array CGH has the ability to refine known consensus regions of alterations. This is important as it allows researchers to narrow their focus to smaller areas of the genome. Second, high-resolution analysis has a greater probability of detecting small novel alterations that may be important for the disease, but may be missed by lower-resolution techniques. As array-based CGH continues to increase in resolution, cancer-causing genes will continue to become easier to discover.
Tumor genomes have different types of genetic instability.
When genomic phenotypes in cancer have a wide range, array CGH will provide significant information on the locations of important cancer genes for some sets of specimens, whereas it will also be uninformative for others. Copy number profiles of cell populations reveal past genomic instability that leads to the clonal expansion of a cell population with a relatively stable genome, or at least stable within its selective environment (22) . In addition to tumor progression, the identification of specific genetic aberrations associated with patient outcomes has been the goal in a number of aCGH studies (45, (53) (54) (55) . The high number of copy number aberrations have been linked with poor patient prognosis for gastric cancer (56) , mantle cell lymphoma (57) , and bladder cancer (58) . Amplification at 5q31-q35 in ovarian cancer has been linked with poor prognosis, whereas losses at 4p16 are associated with a favorable outcome. In All later stage tumors had a greater average number of SeGAs per sample than their precursors. Although many of these secondary genetic changes may be responsible for disease maintenance and proliferation, the majority are not likely to contribute to cancer pathogenesis and are probably a consequence of random events (19) . The increased genomic stability of tumor precursors improves the likelihood that a SeGA discovered may be necessary for the disease. Furthermore, discovering localized regions that contain these genes might be easier, as they may not be 'masked' by the gross genetic alterations occurring at later stages.
If a gene is a target of selection within a region of a copy number increase, it should be overexpressed in tumors in which it is found at an elevated copy number. But, overexpression does not distinguish it from other genes in the aberrant region that may not contribute to tumor development because expression of 40∼60% of all genes may be elevated (18, 64) .
That a gene is always overexpressed when at increased copy number, and is sometimes overexpressed when not present at increased copy number, supports its functional role in cancer (22) . Genes that drive copy number gains may also be altered by mutation (65) . The decrease in expression due to the decrease in copy number is sufficient for the gene to be significant to the tumor in some cases. But, in the classic case of tumor suppressor genes, function is totally abrogated by deletion of all copies of a gene, deletion of one copy, and mutation or epigenetic alteration of the other (66) , or alteration of one copy and replacement of the other by a duplicate of the altered copy. The latter type of aberration results in loss of heterozygosity, not copy number change, and is not detectable by array CGH. Developing SNP profiling technologies may be able to provide additional information concerning these events, perhaps eventually providing information on heterozygosity and dosage for some types of specimens (25, 67) . Candidate genes within recurrent regions of loss can be assessed for expression changes and examined to determine if the remaining copies are mutated or methylated (66) .
2) Identification of segmental copy number changes in genetic diseases
Array CGH was shown to be a specific and sensitive approach in detecting submicroscopic aberrations, such as Prader-Willi syndrome and Angelman syndrome (33) . Several studies using both genome-wide and chromosome-specific arrays support the finding that submicroscopic chromosomal abnormalities can be readily detected with array CGH (68) (69) (70) . 
3) Array CGH as a diagnostic tool and its application in clinical settings
The correlation of cytogenetic aberrations with disease outcomes has already proven to be reliable and is utilized in 
4) Application to normal genomic variations
Array CGH measurements using BAC arrays immediately reveal copy number polymorphisms. Fifty-five unrelated individuals were examined to quantify genetic variation using an array of 2632 LICs (29) Array CGH technology has been used in interspecies comparisons. In a comparison of the human genome against four great ape genomes, using an LIC array of 2,460 BACs, 63 sites of DNA copy number variation between the human and great apes were identified (81) . A significant number of these sites existed in interstitial euchromatin. Using a cDNA array CGH approach, over 29,000 human genes among human, bonobo, chimpanzee, gorilla, and orangutan were compared leading to the identification of ＞800 genes that gave genetic signatures unique to a specific hominoid lineage (82) . There was a more pronounced difference between copy number increases and decreases in humans, and a number of genes amplified are thought to be involved in the structure and function of the brain (73) .
CONCLUSION
In the past decade, genomic arrays have been successfully used to detect genomic amplification and deletions in all types of human tumors. Array CGH can also be used for the identification of yet unidentified abnormalities, as well as the screening of known submicroscopic aberrations in human genetic diseases (33) . Array CGH has elucidated amplifications 
